Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Cantor Fitzgerald
Fuji
Argus Health
Federal Trade Commission
Cerilliant
Queensland Health
Novartis
Baxter
Mallinckrodt

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,906,890

« Back to Dashboard

Which drugs does patent 8,906,890 protect, and when does it expire?


Patent 8,906,890 protects ANGELIQ and is included in one NDA. There have been two Paragraph IV challenges on Angeliq.

This patent has twenty patent family members in seventeen countries.

Summary for Patent: 8,906,890

Title:Very low-dosed solid oral dosage forms for HRT
Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
Inventor(s): Mletzko; Stephan (Berlin, DE), Schurmann; Rolf (Teltow, DE), Gude; Kerstin (Birkenwerder, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:13/087,701
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
ANGELIQ
drospirenone; estradiol
TABLET;ORAL021355-001Feb 29, 2012RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,906,890

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10160072Apr 15, 2010

Non-Orange Book Patents for Patent: 8,906,890

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,592,245Very low-dosed solid oral dosage forms for HRT► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,906,890

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina080912► Subscribe
Australia2011240102► Subscribe
Brazil112012026115► Subscribe
Canada2795801► Subscribe
China102985070► Subscribe
Colombia6630107► Subscribe
Costa Rica20120523► Subscribe
Eurasian Patent Organization026095► Subscribe
Eurasian Patent Organization201201403► Subscribe
European Patent Office2558063► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Medtronic
Chinese Patent Office
Moodys
US Army
McKinsey
QuintilesIMS
Harvard Business School
Teva
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot